AI
MRVI icon

Atom Investors’s Maravai LifeSciences MRVI Stock Holding History

Atom Investors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-55,047
Closed -$158K – 730
2025
Q3 		$158K Buy
+55,047
New +$141K 0.01% 529
2024
Q2 		– Sell
-19,077
Closed -$165K – 595
2024
Q1 		$165K Buy
+19,077
New +$129K 0.02% 495

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atom Investors's MRVI Position: Q4 2025 in Review

Atom Investors sold out of Maravai LifeSciences (MRVI) in Q4 2025, closing a stake of 55,047 shares — an estimated $158K sold.

Atom Investors first reported a position in MRVI in Q1 2024 and held it in 2 quarters. The position peaked at $165K in Q1 2024. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

  • Atom Investors reported no remaining Maravai LifeSciences position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 55,047 Maravai LifeSciences shares in Q4 2025, an estimated $158K.
  • Atom Investors first reported a position in Maravai LifeSciences in Q1 2024 and held it in 2 quarters.
  • Atom Investors's Maravai LifeSciences position peaked at $165K in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.